Kulkarni Samarth bought CRSP
August 16, 2025 · Form 4 insider transaction
Kulkarni Samarth bought 25,000 shares of CRISPR Therapeutics AG, a transaction worth N/A. The trade was recorded as option exercise and disclosed on an SEC Form 4, filed 3 days after the transaction.
Direction
Acquired (buy-side)
Shares
25,000
Price
N/A
Total value
N/A
InsiderKulkarni Samarth
RoleOfficer, Director
SecurityCommon Shares
Transaction codeM: Option exercise
Transaction dateAugust 16, 2025
Filing dateAugust 19, 2025
Shares owned after220,085
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.